Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All Pharmacological Articles

Inside the potential of glial cell modulators for disease modification and pain management including OUD, opioid tolerance, and hyperalgesia.
The majority of Medicare Part D patients diagnosed with OUD were not identified as overutilizers.
Direct-acting opioids may be a better options for depressed patients on SSRIs.
Results bring into question the high cost of the products and use over FDA-approved variations.
Tracking the prevention methods of prescription opioid misuse and overdose deaths by 2025.
Benzodiazepines are accounted for a growing number of overdose-related deaths
A compounded formula using codeine could lower patients’ overall opioid doses, according to one doctor's novel research.
Beyond the opioid crisis, new challenges—and hopes—await the pain practice community.
Insurance companies decline to continue paying for opioid medications, citing opioid-induced hyperalgesia (OIH). Why?
Inside the unique properties of Nektar Therapeutics’ new abuse-deterrent opioid, NKTR-181, and its potential for treating low back pain.
New Jersey is the latest state to allow medical cannabis to be used as an adjunct to medically assisted treatment for Opioid Use Disorder (read the full story). Here, PPM
New Jersey becomes the third state to allow medical marijuana treatment for opioid use disorder.
In a close vote, panel members remain divided. More news coming soon.
While opioid prescribing rates decreased over a nine-year period, certain factors led to differences in prescribing.
While use was associated with reduced pain and improved physical functioning, there was an increased incidence of vomiting.
close X